Universidade de São Paulo, São Paulo, SP, Brazil.
Clinics (Sao Paulo). 2012;67(3):231-5. doi: 10.6061/clinics/2012(03)05.
Clinical-laboratory and evolutionary analysis of twenty-eight patients with Wilson's disease.
Twenty-eight children (twelve females and sixteen males) with Wilson's disease were evaluated retrospectively between 1987 and 2009, with a follow-up of 72 months (1 - 240 months). The clinical, laboratory, and histologic features at diagnosis were recorded at the end of the study.
The median age at diagnosis was 11 years (2 - 18 years). Twelve patients were asymptomatic, seven had hepatitis symptoms, five had raised aminotransferase levels, three had hepatomegaly associated with neurological disorders, one had fulminant hepatitis with hemolytic anemia, and six patients presented with a Kayser-Fleischer ring. A histological analysis revealed that six children had chronic hepatitis, seven had cirrhosis, two had steatosis, one had portal fibrosis, and one had massive necrosis. The treatment consisted of D-penicillamine associated with pyridoxine for 26 patients. Adverse effects were observed in the other two patients: one presented with uncontrollable vomiting and the other demonstrated elastosis perforans serpiginosa. At the end of the study, all 26 treated patients were asymptomatic. Twenty-four of the patients were treated with D-penicillamine and pyridoxine, and two were treated with trientine and zinc sulfate. A liver transplant was performed in one patient with fulminant hepatitis, but the final patient died 48 hours after admission to the intensive care unit.
Family screenings associated with early treatment are important in preventing Wilson's disease symptoms and potentially fatal disease progression. The study suggests that Wilson's disease must be ruled out in children older than two years presenting with abnormal levels of hepatic enzymes because of the heterogeneity of symptoms and the encouraging treatment results obtained so far.
对 28 例威尔逊病患者的临床-实验室和进化分析。
回顾性分析 1987 年至 2009 年间 28 例(12 例女性,16 例男性)威尔逊病患儿的临床、实验室和组织学特征,随访时间为 72 个月(1-240 个月)。研究结束时记录了诊断时的临床、实验室和组织学特征。
诊断时的中位年龄为 11 岁(2-18 岁)。12 例无症状,7 例有肝炎症状,5 例转氨酶升高,3 例肝肿大伴神经系统障碍,1 例暴发性肝炎伴溶血性贫血,6 例有凯瑟-弗莱舍环。组织学分析显示,6 例患儿为慢性肝炎,7 例为肝硬化,2 例为脂肪变性,1 例为门脉纤维化,1 例为大片坏死。26 例患儿采用 D-青霉胺联合吡哆醇治疗。另 2 例患儿出现不良反应:1 例出现无法控制的呕吐,另 1 例出现弹性穿孔丝虫病。研究结束时,所有 26 例治疗患者均无症状。24 例患者接受 D-青霉胺和吡哆醇治疗,2 例患者接受三乙烯四胺和硫酸锌治疗。1 例暴发性肝炎患者行肝移植,但最后 1 例患者在入住重症监护病房 48 小时后死亡。
家族筛查结合早期治疗对于预防威尔逊病症状和潜在致命疾病进展非常重要。本研究表明,对于年龄大于 2 岁、肝酶水平异常的儿童,必须排除威尔逊病,因为症状的异质性和迄今为止获得的令人鼓舞的治疗结果。